Scheme 1: Corrected Scheme 9 of the original article. N/P-doped hollow CDs for efficient drug delivery of doxorubicin.
Scheme 2: Corrected Scheme 15 of the original article. N/P-doped green-emissive CDs working in tandem with hyaluronic acid-coated AuNPs to monitor hyaluronidase activity.
Scheme 3: Corrected Scheme 20 of the original article. Different polysaccharide-derived CDs in the presence of PEG-200 and how the starting material composition is conferred to the CD products.
Scheme 4: Corrected Scheme 22 of the original article. Hyaluronic acid (HA) and glycine-derived CDs, suspected to be decorated in unreacted HA, allowing receptor-mediated cell uptake.
